Z. Cinza

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti‐hepatitis B vaccination

E. Ferrer, B. Acevedo, G. Márquez, 2010, The journal of gene medicine.

Immunogenicity of CIGB‐230, a therapeutic DNA vaccine preparation, in HCV‐chronically infected individuals in a Phase I clinical trial

J. Dubuisson, F. Helle, B. Grá, 2009, Journal of viral hepatitis.

Full validation of an ELISA for quantification of antibodies against Haemophilus influenzaetype b capsular polysaccharide

Z. Cinza, M. Pérez-Bernal, M. Izquierdo, 2021, Journal of Applied Biotechnology & Bioengineering.

HeberNasvac, a Therapeutic Vaccine for Chronic Hepatitis B, Stimulates Local and Systemic Markers of Innate Immunity: Potential Use in SARS-CoV-2 Postexposure Prophylaxis

M. Mahtab, G. Guillén, Sheikh M. F. Akbar, 2021, Euroasian journal of hepato-gastroenterology.

[Impact of an anti-hepatitis B virus (HBV) immunization program in patients undergoing dialysis in Havana, Cuba].

E. Pentón, Z. Cinza, N. Levy, 2000, Investigación Clínica.

Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults

A. Musacchio, Elizeth García, C. Valenzuela, 2011, Human vaccines.

Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac

Y. Lobaina, F. Freyre, V. Muzio, 2018, Euroasian journal of hepato-gastroenterology.

Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers

G. Guillén, Ricardo Silva, A. Álvarez, 2001, Biotechnology and applied biochemistry.